CareDx, Inc. (CDNA) stock
CDNANasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 12/3024% above fair value
$74.56+0.84 (+1.14%)
Close on Nov 17, 2026Market cap $3.92BP/E 31.2Yield –
CareDx r&d expenses
Research and development expenses are spending on new products and technology.
CareDx's R&D Expenses for the twelve months ending Sep 30, 2026 was $84.42M, up 22.8% year over year. For fiscal 2025 it was $71.43M, down 1.5% from the year before. Over ten years it grew 22.6% a year on average. The highest annual figure on record is $90.39M in fiscal 2022.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $71.43M | -1.5% |
| FY2024 | Dec 31, 2024 | $72.51M | -12.0% |
| FY2023 | Dec 31, 2023 | $82.42M | -8.8% |
| FY2022 | Dec 31, 2022 | $90.39M | +18.1% |
| FY2021 | Dec 31, 2021 | $76.53M | +56.4% |
| FY2020 | Dec 31, 2020 | $48.94M | +59.4% |
| FY2019 | Dec 31, 2019 | $30.71M | +111.6% |
| FY2018 | Dec 31, 2018 | $14.51M | +17.2% |
| FY2017 | Dec 31, 2017 | $12.39M | +0.0% |
| FY2016 | Dec 31, 2016 | $12.39M | +32.7% |
| FY2015 | Dec 31, 2015 | $9.33M | +142.7% |
| FY2014 | Dec 31, 2014 | $3.85M | +21.1% |
| FY2013 | Dec 31, 2013 | $3.18M | -33.2% |
| FY2012 | Dec 31, 2012 | $4.75M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $21.32M | +27.2% |
| Q2 FY2026 | Jun 30, 2026 | $22.38M | +33.0% |
| Q1 FY2026 | Mar 31, 2026 | $21.42M | +15.6% |
| Q4 FY2025 | Dec 31, 2025 | $19.31M | +16.2% |
| Q3 FY2025 | Sep 30, 2025 | $16.77M | -4.1% |
| Q2 FY2025 | Jun 30, 2025 | $16.83M | -14.5% |
| Q1 FY2025 | Mar 31, 2025 | $18.52M | -1.0% |
| Q4 FY2024 | Dec 31, 2024 | $16.62M | -11.7% |
| Q3 FY2024 | Sep 30, 2024 | $17.49M | -8.0% |
| Q2 FY2024 | Jun 30, 2024 | $19.69M | -2.7% |
| Q1 FY2024 | Mar 31, 2024 | $18.71M | -23.2% |
| Q4 FY2023 | Dec 31, 2023 | $18.83M | -20.1% |
| Q3 FY2023 | Sep 30, 2023 | $19.00M | -14.8% |
| Q2 FY2023 | Jun 30, 2023 | $20.23M | -10.6% |
| Q1 FY2023 | Mar 31, 2023 | $24.36M | +11.3% |
| Q4 FY2022 | Dec 31, 2022 | $23.57M | +6.9% |
| Q3 FY2022 | Sep 30, 2022 | $22.31M | +14.7% |
| Q2 FY2022 | Jun 30, 2022 | $22.63M | +18.9% |
| Q1 FY2022 | Mar 31, 2022 | $21.88M | +36.7% |
| Q4 FY2021 | Dec 31, 2021 | $22.05M | +65.4% |
| Q3 FY2021 | Sep 30, 2021 | $19.44M | +55.8% |
| Q2 FY2021 | Jun 30, 2021 | $19.04M | +45.0% |
| Q1 FY2021 | Mar 31, 2021 | $16.00M | +59.8% |
| Q4 FY2020 | Dec 31, 2020 | $13.33M | +48.9% |
| Q3 FY2020 | Sep 30, 2020 | $12.47M | +46.4% |
| Q2 FY2020 | Jun 30, 2020 | $13.13M | +72.1% |
| Q1 FY2020 | Mar 31, 2020 | $10.01M | +78.4% |
| Q4 FY2019 | Dec 31, 2019 | $8.95M | +136.5% |
| Q3 FY2019 | Sep 30, 2019 | $8.52M | +120.3% |
| Q2 FY2019 | Jun 30, 2019 | $7.63M | +118.2% |
| Q1 FY2019 | Mar 31, 2019 | $5.61M | +66.7% |
| Q4 FY2018 | Dec 31, 2018 | $3.78M | +24.9% |
| Q3 FY2018 | Sep 30, 2018 | $3.87M | +30.7% |
| Q2 FY2018 | Jun 30, 2018 | $3.50M | +12.1% |
| Q1 FY2018 | Mar 31, 2018 | $3.37M | +2.6% |
| Q4 FY2017 | Dec 31, 2017 | $3.03M | -4.0% |
| Q3 FY2017 | Sep 30, 2017 | $2.96M | – |
| Q2 FY2017 | Jun 30, 2017 | $3.12M | – |
| Q1 FY2017 | Mar 31, 2017 | $3.28M | – |
| Q4 FY2016 | Dec 31, 2016 | $3.15M | – |
See a number that looks wrong?